Rheumatology (Oxford, England) · 2026
Prediction of foetal atrioventricular conduction using maternal disease, treatment and anti-Ro/La autoantibody levels.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Martin de Frémont Grégoire, Rudolph Lisa, da Silva Rodrigues Rui, Hedlund Malin, Tršelič Tilen, Wegner Sven, Orillion Ashley, Painter Jennifer, Zaha Rebecca, Eliasson Håkan, Nordenstam Felicia, Bergman Gunnar, Sonesson Sven-Erik, Wahren-Herlenius Marie
Аннотация
OBJECTIVES: To investigate the relationship between maternal disease, anti-rheumatic treatment, autoantibody levels and foetal atrioventricular (AV) conduction.
METHODS: A total of 324 pregnancies from two groups of anti-Ro/La autoantibody-positive women were included. The Surveillance group consisted of pregnancies with known anti-Ro positivity followed from early pregnancy; n = 302, including nine with AV block (AVB), and the Bradycardia group with no prior knowledge of anti-Ro/La autoantibodies and referred upon detection of foetal bradycardia, with a subsequent AVB II-III diagnosis (n = 22). Foetal AV conduction and routine anti-Ro52, anti-Ro60 and anti-La autoantibody levels were analysed.
RESULTS: Women with primary Sjögren disease (SjD) had longer foetal AV time intervals (130.5 ± 11.9 vs 125.8 ± 8.7 ms, P = 0.002) compared with autoantibody-positive women with neither SjD nor SLE. Notably, AZA, mostly used in women with SLE, was associated with shorter foetal AV time intervals compared with autoantibody-positive pregnancies without AZA treatment (122.5 ± 8.9 vs 128.7 ± 11.0 ms, P = 0.038). For antibody-based prediction, anti-Ro52, anti-Ro60 and anti-La antibody levels obtained from routine assays could identify nearly 20% of pregnancies as low risk, and high levels (≥8 U/ml) of anti-La antibodies were associated with an increased risk of AVB I-III (OR = 6.0, 1.26-28.5). However, the positive predictive value for AVB II-III of the three autoantibodies did not reach 5% for a sensitivity of 100%.
CONCLUSION: This report, based on over 20 years of surveillance of anti-Ro positive pregnancies, identifies associations between maternal disease, their treatments and foetal AV conduction. Routine detection assays for anti-Ro/La antibodies had low performance in predicting AVB among an anti-Ro/La positive population.
METHODS: A total of 324 pregnancies from two groups of anti-Ro/La autoantibody-positive women were included. The Surveillance group consisted of pregnancies with known anti-Ro positivity followed from early pregnancy; n = 302, including nine with AV block (AVB), and the Bradycardia group with no prior knowledge of anti-Ro/La autoantibodies and referred upon detection of foetal bradycardia, with a subsequent AVB II-III diagnosis (n = 22). Foetal AV conduction and routine anti-Ro52, anti-Ro60 and anti-La autoantibody levels were analysed.
RESULTS: Women with primary Sjögren disease (SjD) had longer foetal AV time intervals (130.5 ± 11.9 vs 125.8 ± 8.7 ms, P = 0.002) compared with autoantibody-positive women with neither SjD nor SLE. Notably, AZA, mostly used in women with SLE, was associated with shorter foetal AV time intervals compared with autoantibody-positive pregnancies without AZA treatment (122.5 ± 8.9 vs 128.7 ± 11.0 ms, P = 0.038). For antibody-based prediction, anti-Ro52, anti-Ro60 and anti-La antibody levels obtained from routine assays could identify nearly 20% of pregnancies as low risk, and high levels (≥8 U/ml) of anti-La antibodies were associated with an increased risk of AVB I-III (OR = 6.0, 1.26-28.5). However, the positive predictive value for AVB II-III of the three autoantibodies did not reach 5% for a sensitivity of 100%.
CONCLUSION: This report, based on over 20 years of surveillance of anti-Ro positive pregnancies, identifies associations between maternal disease, their treatments and foetal AV conduction. Routine detection assays for anti-Ro/La antibodies had low performance in predicting AVB among an anti-Ro/La positive population.